Sobi and Apellis data underscore Aspaveli potential

Swedish Orphan Biovitrum (STO: SOBI) and US biopharma Apellis Pharmaceuticals (Nasdaq: APLS) have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

The C3 therapy is designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. 

It is under investigation for rare diseases across hematology and nephrology and has won approval for the treatment of paroxysmal nocturnal hemoglobinuria in the USA, Europe and other markets.